Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy
Year: 2021
Type: article
Study design: Observational Study
Source: European Journal of Cancer
Authors: Adriana Hepner, Victoria G. Atkinson, James Larkin, Rebecca A. Burrell, Matteo S. Carlino, Douglas B. Johnson, Lisa Zimmer, Katy K. Tsai, Oliver Klein, Serigne N. Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Ines Pires da Silva, Camille Gerard, Olivier Michielin, Georgina V. Long, Alexander M. Menzies
Institutions: The University of Sydney, Instituto do Câncer do Estado de São Paulo, Melanoma Institute Australia, Greenslopes Private Hospital, Royal Marsden NHS Foundation Trust, Westmead Hospital, Vanderbilt University Medical Center, Essen University Hospital, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Austin Health, Alfred Health, Monash University, Cairns Hospital, Hobart Private Hospital, Centre Hospitalier Universitaire Vaudois, Royal North Shore Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Award: G5229117719
OpenAlex ID: W3173664330